Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Ultragenyx stock

Learn how to easily invest in Ultragenyx stock.

Ultragenyx is a biotechnology business based in the US. Ultragenyx shares (RARE) are listed on the NASDAQ and all prices are listed in US Dollars. Ultragenyx employs 1,119 staff and has a trailing 12-month revenue of around $334.3 million.

How to buy shares in Ultragenyx

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – RARE – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Ultragenyx stock price (NASDAQ: RARE)

Use our graph to track the performance of RARE stocks over time.

Ultragenyx shares at a glance

Information last updated 2022-09-25.
Latest market close$41.41
52-week range$40.84 - $91.10
50-day moving average $50.07
200-day moving average $63.12
Wall St. target price$111.76
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-6.87

Buy Ultragenyx shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 7 of 7
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.
Stocks, Options, ETFs
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Ultragenyx stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Ultragenyx price performance over time

Historical closes compared with the close of $41.41 from 2022-09-30

1 week (2022-09-23) -0.22%
1 month (2022-09-02) -13.28%
3 months (2022-07-01) -33.90%
6 months (2022-03-29) N/A
1 year (2021-10-01) -52.84%
2 years (2020-10-02) -50.94%
3 years (2019-10-02) 42.22
5 years (2017-09-29) 53.26

Ultragenyx financials

Revenue TTM $334.3 million
Gross profit TTM $-161,755,000
Return on assets TTM -20.76%
Return on equity TTM -61.32%
Profit margin -151.34%
Book value $9.69
Market capitalisation $2.9 billion

TTM: trailing 12 months

Ultragenyx share dividends

We're not expecting Ultragenyx to pay a dividend over the next 12 months.

Have Ultragenyx's shares ever split?

Ultragenyx's shares were split on a 1:3 basis on 17 January 2014. So if you had owned 3 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Ultragenyx shares – just the quantity. However, indirectly, the new 200% higher share price could have impacted the market appetite for Ultragenyx shares which in turn could have impacted Ultragenyx's share price.

Ultragenyx share price volatility

Over the last 12 months, Ultragenyx's shares have ranged in value from as little as $40.84 up to $91.1. A popular way to gauge a stock's volatility is its "beta".

RARE.US volatility(beta: 1.22)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ultragenyx's is 1.2189. This would suggest that Ultragenyx's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Ultragenyx overview

Ultragenyx Pharmaceutical Inc. , a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co. , Ltd.

Frequently asked questions

What percentage of Ultragenyx is owned by insiders or institutions?
Currently 5.033% of Ultragenyx shares are held by insiders and 94.299% by institutions.
How many people work for Ultragenyx?
Latest data suggests 1,119 work at Ultragenyx.
When does the fiscal year end for Ultragenyx?
Ultragenyx's fiscal year ends in December.
Where is Ultragenyx based?
Ultragenyx's address is: 60 Leveroni Court, Novato, CA, United States, 94949
What is Ultragenyx's ISIN number?
Ultragenyx's international securities identification number is: US90400D1081
What is Ultragenyx's CUSIP number?
Ultragenyx's Committee on Uniform Securities Identification Procedures number is: 90400D108

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site